Exelixis Inc (EXEL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $16.84B
Last updated: Nov 17, 2026 at 11:05 AM ET
Exelixis Inc (EXEL) Financials: Revenue, Profit and Cash Flow
Exelixis reported revenue of $2.32B for the fiscal year ended Dec 31, 2025, up 7.0% from the year before. That year, net income was $782.57M with a net margin of 33.7%, operating cash flow was $884.27M and free cash flow was $875.84M. The quarter ended Jun 30, 2026 had revenue of $628.69M and net income of $212.05M.
Revenue and Margins
The operating margin was 37.6% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $191.45M, a compound annual rate of 31.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.32B | +7.0% | 96.4% | 37.6% | 33.7% |
| Dec 2024 | $2.17B | +18.5% | 96.5% | 27.9% | 24.0% |
| Dec 2023 | $1.83B | +13.6% | 96.0% | 9.3% | 11.4% |
| Dec 2022 | $1.61B | +12.3% | 96.4% | 12.5% | 11.3% |
| Dec 2021 | $1.43B | +45.3% | 96.3% | 20.0% | 16.1% |
| Dec 2020 | $987.54M | +2.0% | 96.3% | 11.1% | 11.3% |
| Dec 2019 | $967.77M | +13.3% | 96.6% | 38.2% | 33.2% |
| Dec 2018 | $853.83M | +88.7% | 96.9% | 51.4% | 80.8% |
| Dec 2017 | $452.48M | +136.3% | 96.7% | 36.7% | 34.1% |
| Dec 2016 | $191.45M | N/A | 96.6% | -14.7% | -36.7% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 50.1% from the year before. In the quarter ended Jun 2026, net income rose 14.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32B | $2.17B | $1.83B | $1.61B | $1.43B | $987.54M | $967.77M | $853.83M | $452.48M | $191.45M |
| Cost of revenue | $83.70M | $76.22M | $72.55M | $57.91M | $52.87M | $36.27M | $33.10M | $26.35M | $15.07M | $6.55M |
| Gross profit | $2.24B | $2.09B | $1.76B | $1.55B | $1.38B | $951.27M | $934.68M | $827.48M | $437.41M | $184.90M |
| Research and development | $825.00M | $910.41M | $1.04B | $891.81M | $693.72M | $547.85M | $336.96M | $182.26M | $112.17M | $95.97M |
| Operating income | $872.19M | $604.62M | $170.88M | $201.48M | $286.67M | $110.06M | $369.47M | $438.86M | $165.91M | -$28.12M |
| Net income | $782.57M | $521.27M | $207.76M | $182.28M | $231.06M | $111.78M | $321.01M | $690.07M | $154.23M | -$70.22M |
| EBITDA | $901.05M | $633.29M | $196.69M | $222.16M | $300.11M | $120.11M | $378.50M | $444.17M | N/A | N/A |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $628.69M | $610.81M | $598.66M | $597.75M | $568.26M | $555.45M | $566.75M | $539.54M | $637.18M | $425.23M | $479.65M | $471.92M |
| Gross profit | $608.03M | $590.86M | $572.18M | $579.18M | $548.79M | $536.27M | $546.79M | $522.21M | $619.51M | $403.97M | $457.90M | $453.15M |
| Operating income | $248.41M | $251.34M | $235.22M | $236.54M | $213.58M | $186.86M | $163.21M | $136.07M | $275.87M | $29.46M | $81.79M | -$17.58M |
| Net income | $212.05M | $210.47M | $244.53M | $193.58M | $184.85M | $159.62M | $139.86M | $117.97M | $226.12M | $37.32M | $85.52M | $1.04M |
Balance Sheet
As of Dec 2025, cash and equivalents of $482.49M were 17.0% of total assets of $2.84B, against total liabilities of $683.10M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.84B | $2.95B | $2.94B | $3.07B | $2.62B | $2.14B | $1.89B | $1.42B | $655.29M | $595.74M |
| Current assets | $1.44B | $1.47B | $1.32B | $1.62B | $1.83B | $1.45B | $1.01B | $897.02M | $484.87M | $469.00M |
| Cash and equivalents | $482.49M | $217.37M | $262.99M | $501.19M | $647.17M | $319.22M | $266.50M | $314.77M | $183.16M | $151.69M |
| Total liabilities | $683.10M | $703.49M | $678.45M | $583.06M | $405.62M | $258.22M | $199.70M | $134.83M | $370.33M | $506.42M |
| Short-term debt | N/A | $25.01M | $25.71M | $17.66M | $8.74M | $3.02M | $2.73M | $56.85M | $57.46M | $189.12M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $12.10M | $408.00K | $0 |
| Shareholder equity | $2.16B | $2.24B | $2.26B | $2.49B | $2.21B | $1.88B | $1.69B | $1.29B | $284.96M | $89.32M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $2.49B | $2.59B | $2.84B | $2.82B | $2.68B | $2.84B | $2.95B | $2.96B | $2.77B | $2.80B | $2.94B | $2.98B |
| Total liabilities | $650.47M | $657.85M | $683.10M | $662.85M | $644.54M | $706.22M | $703.49M | $684.86M | $653.39M | $675.74M | $678.45M | $629.29M |
| Cash and equivalents | $281.45M | $226.15M | $482.49M | $376.30M | $164.43M | $183.75M | $217.37M | $258.35M | $198.46M | $259.56M | $262.99M | $396.86M |
| Shareholder equity | $1.84B | $1.94B | $2.16B | $2.16B | $2.03B | $2.13B | $2.24B | $2.28B | $2.12B | $2.13B | $2.26B | $2.35B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 99.0% of operating cash flow. Share repurchases came to 108.2% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $884.27M | $699.97M | $333.32M | $362.61M | $400.80M | $208.98M | $526.96M | $415.72M | $165.61M | $210.40M |
| Capital expenditures | $8.43M | $28.43M | $40.47M | $27.71M | $54.23M | $30.34M | $12.83M | $33.30M | $21.14M | $1.70M |
| Free cash flow | $875.84M | $671.54M | $292.86M | $334.91M | $346.58M | $178.64M | $514.12M | $382.42M | $144.47M | $208.70M |
| Share repurchases | $947.51M | $652.03M | $550.38M | $0 | $0 | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $350.44M | -$116.78M | -$26.95M | -$524.41M | -$42.88M | -$131.22M | -$587.25M | -$297.85M | $36.80M | -$214.55M |
| Financing cash flow | -$969.59M | -$628.81M | -$546.05M | $586.00K | -$14.80M | -$25.13M | $12.55M | $9.69M | -$169.93M | $15.70M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $307.74M | $251.84M | $333.51M | $290.32M | $48.99M | $211.44M | $240.26M | $271.34M | $119.55M | $68.82M | $10.57M | $117.37M |
| Capital expenditures | $6.82M | $1.51M | $1.16M | $1.48M | $2.84M | $2.95M | $3.98M | $8.20M | $6.57M | $9.69M | $13.13M | $9.37M |
| Free cash flow | $300.93M | $250.34M | $332.36M | $288.84M | $46.16M | $208.49M | $236.29M | $263.14M | $112.98M | $59.13M | -$2.56M | $107.99M |
Frequently Asked Questions About EXEL
What is Exelixis' annual revenue?
Exelixis reported revenue of $2.32B for the fiscal year ended Dec 31, 2025.
How fast is Exelixis' revenue growing?
Revenue was up 7.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.9%.
Is Exelixis profitable?
Yes. Exelixis reported net income of $782.57M for the fiscal year ended Dec 31, 2025, with a net margin of 33.7%.
How much free cash flow does EXEL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $884.27M minus capital expenditures of $8.43M produced free cash flow of $875.84M.
How much debt does Exelixis have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $482.49M.
EXEL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors